Ambrosan^® (Tablets, Solution) Instructions for Use

ATC Code

R05CB06 (Ambroxol)

Active Substance

Ambroxol (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Mucolytic and expectorant drug

Pharmacotherapeutic Group

Mucolytic expectorant

Pharmacological Action

Mucolytic and expectorant agent, is an active N-demethylated metabolite of bromhexine. It has secretomotor, secretolytic, and expectorant actions.

It stimulates the serous cells of the bronchial mucosa, increases the motor activity of the ciliated epithelium by acting on type 2 pneumocytes in the alveoli and Clara cells in the bronchioles, and enhances the production of endogenous surfactant, a surface-active substance that ensures the sliding of bronchial secretions in the airway lumen.

Ambroxol increases the proportion of the serous component in the bronchial secretion, improving its structure and contributing to a decrease in viscosity and liquefaction of sputum; as a result, mucociliary transport is improved and the removal of sputum from the bronchial tree is facilitated.

When Ambroxol is taken orally, the effect occurs, on average, after 30 minutes and lasts for 6-12 hours, depending on the single dose.

Pharmacokinetics

After oral administration, Ambroxol is rapidly and almost completely absorbed. T_max is 1-3 hours. Plasma protein binding is approximately 85%. It crosses the placental barrier and is excreted in breast milk.

It is metabolized in the liver to form metabolites (dibromanthranilic acid, glucuronic conjugates), which are excreted by the kidneys. It is excreted mainly by the kidneys – 90% as metabolites, less than 10% unchanged. T_1/2 from plasma is 7-12 hours. The T_1/2 of ambroxol and its metabolites is approximately 22 hours.

Due to high protein binding and a large V_d, as well as slow back penetration from tissues into the blood, significant excretion of ambroxol does not occur during dialysis or forced diuresis.

The clearance of ambroxol in patients with severe hepatic impairment is reduced by 20-40%. In severe renal failure, the T_1/2 of ambroxol metabolites is increased.

Indications

Diseases of the respiratory tract accompanied by the production of viscous sputum and difficulty in expectoration: acute and chronic bronchitis; pneumonia; bronchial asthma; bronchiectasis; COPD.

ICD codes

Dosage Regimen

Establish the dosage individually based on the clinical situation, indication, patient age, and the specific formulation used.

For adults and children over 12 years, administer 30 mg three times daily using standard tablets or solution.

After 2-3 days of treatment, if a satisfactory therapeutic effect is achieved, transition to a maintenance dose of 30 mg twice daily.

For children aged 6 to 12 years, administer 15 mg (half a 30 mg tablet or 2.5 ml of solution) three times daily.

For children aged 2 to 5 years, administer 7.5 mg (one-quarter of a 30 mg tablet or 1.25 ml of solution) twice daily; the oral solution is the preferred formulation for this age group.

For children under 2 years of age, administer 7.5 mg (1.25 ml of solution) twice daily; treatment must be initiated and supervised by a physician.

Adhere strictly to the age-specific contraindications: do not use tablets in children under 6 years and prolonged-release formulations in children under 12 years.

Administer the dose during or after a meal with a sufficient amount of liquid.

For the oral solution, use the measuring cup provided to ensure accurate dosing; do not use immediately before bedtime.

The duration of treatment depends on the underlying disease; for acute conditions, a course of 7-14 days is typically sufficient.

In patients with severe renal or hepatic impairment, consider increasing the dosing interval or reducing the dose under medical supervision.

Adverse Reactions

Allergic reactions rarely – skin rash, urticaria, exanthema, facial edema, dyspnea, itching, fever; frequency unknown – anaphylactic reactions, including anaphylactic shock, angioedema, skin itching, allergic contact dermatitis.

From the digestive system often – nausea; infrequently – vomiting, diarrhea, dyspepsia, abdominal pain.

From the nervous system often – dysgeusia.

From the skin and subcutaneous tissues very rarely – toxic epidermal necrolysis (Lyell’s syndrome), Stevens-Johnson syndrome; frequency unknown – acute generalized exanthematous pustulosis.

From the respiratory system often – decreased sensitivity in the oral cavity or pharynx; rarely – dryness of the respiratory mucosa, rhinorrhea; in isolated cases – dryness of the pharyngeal mucosa.

Contraindications

Hypersensitivity to ambroxol or auxiliary components of the drugs; first trimester of pregnancy; lactation period (breastfeeding); children under 6 years of age (for tablets); children under 12 years of age (for prolonged-release dosage forms).

With caution

Impaired bronchial motility and increased mucus secretion (for example, in the rare immotile cilia syndrome); renal failure and/or severe hepatic failure; gastric and duodenal ulcer (including history); second and third trimesters of pregnancy; children under 2 years of age (oral solution; only as prescribed by a doctor).

Use in Pregnancy and Lactation

Ambroxol is contraindicated in the first trimester of pregnancy. If it is necessary to use it in the second and third trimesters, the potential benefit of therapy for the mother and the possible risk to the fetus should be assessed.

If it is necessary to use ambroxol during lactation, the issue of discontinuing breastfeeding should be decided.

Use in Hepatic Impairment

Use with caution in severe hepatic insufficiency.

Use in Renal Impairment

Use with caution in renal failure.

Pediatric Use

It can be used in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the ambroxol drug labels regarding contraindications for the use of specific ambroxol dosage forms in children of different ages.

Geriatric Use

The drug is approved for use in elderly patients.

Special Precautions

Ambroxol should not be taken simultaneously with antitussive drugs that may inhibit the cough reflex, such as codeine, as this may hinder the removal of liquefied sputum from the bronchi.

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking Ambroxol are not recommended to perform breathing exercises due to difficulty in expectoration. In patients in serious condition, aspiration of liquefied sputum should be performed.

Ambroxol should not be taken immediately before bedtime.

In patients with bronchial asthma, Ambroxol may intensify coughing.

In patients with severe skin lesions – Stevens-Johnson syndrome or toxic epidermal necrolysis – an influenza-like condition may be observed in the early phase: fever, body aches, rhinitis, cough, pharyngitis. With symptomatic therapy, mucolytic agents such as ambroxol hydrochloride may be erroneously prescribed.

Drug Interactions

Antitussives (e.g., codeine) – due to suppression of the cough reflex, accumulation of sputum in the airway lumen with difficulty in its removal is possible (simultaneous use is not recommended).

Amoxicillin, doxycycline, cefuroxime, erythromycin – increased penetration of antibiotics into the bronchial secretion.

Storage Conditions

Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.